Timm MM - Search Results

1

MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.

Wu X, Nowakowski KE, Abeykoon JP, Manske M, Stenson MJ, Timm MM, Hanson CA, Van Dyke DL, Dasari S, Witzig TE. Wu X, et al. Among authors: timm mm. Eur J Haematol. 2021 Oct;107(4):458-465. doi: 10.1111/ejh.13682. Epub 2021 Jul 18. Eur J Haematol. 2021. PMID: 34214199 Free PMC article.

2

Measurement of the cell proliferation rate of bone marrow erythroid precursors by flow cytometry: initial applications to multiple myeloma.

Timm M, Kimlinger TK, Hanson C, Witzig TE. Timm M, et al. Leuk Lymphoma. 1998 Jul;30(3-4):353-9. doi: 10.3109/10428199809057546. Leuk Lymphoma. 1998. PMID: 9713965

3

Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders.

Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Witzig TE, et al. Br J Haematol. 1999 Jan;104(1):131-7. doi: 10.1046/j.1365-2141.1999.01136.x. Br J Haematol. 1999. PMID: 10027725 Free article.

4

Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.

Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. Witzig TE, et al. Clin Cancer Res. 2000 Feb;6(2):681-92. Clin Cancer Res. 2000. PMID: 10690554

5

Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.

Dingli D, Timm M, Russell SJ, Witzig TE, Rajkumar SV. Dingli D, et al. Clin Cancer Res. 2002 Dec;8(12):3948-54. Clin Cancer Res. 2002. PMID: 12473611

6

Flow cytometric methods for detection and quantification of apoptosis.

Steensma DP, Timm M, Witzig TE. Steensma DP, et al. Methods Mol Med. 2003;85:323-32. doi: 10.1385/1-59259-380-1:323. Methods Mol Med. 2003. PMID: 12710217 Review. No abstract available.

7

Expression of VEGF and its receptors by myeloma cells.

Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Kumar S, et al. Leukemia. 2003 Oct;17(10):2025-31. doi: 10.1038/sj.leu.2403084. Leukemia. 2003. PMID: 14513053

8

Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.

Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Thompson MA, et al. Among authors: timm mm. Br J Haematol. 2003 Oct;123(2):305-8. doi: 10.1046/j.1365-2141.2003.04605.x. Br J Haematol. 2003. PMID: 14531913 Free article. Clinical Trial.

9

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV. Kumar S, et al. Blood. 2004 Aug 15;104(4):1159-65. doi: 10.1182/blood-2003-11-3811. Epub 2004 May 6. Blood. 2004. PMID: 15130943 Free article.

10

Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis.

Manske MK, Zuckerman NS, Timm MM, Maiden S, Edelman H, Shahaf G, Barak M, Dispenzieri A, Gertz MA, Mehr R, Abraham RS. Manske MK, et al. Among authors: timm mm. Clin Immunol. 2006 Jul;120(1):106-20. doi: 10.1016/j.clim.2006.01.008. Epub 2006 Mar 3. Clin Immunol. 2006. PMID: 16515886

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters